Grifols' Talecris purchase hits snag; Antisense's trabedersen gets good Phase IIb news;

 @FierceBiotech: In bombshell, DOJ reverses stance on gene patents. Report | Follow @FierceBiotech

 @JohnCFierce: Glaxo inks $231M pact for Phase III Amicus drug. Another rare disease pact for the pharma giant. Article  | Follow @JohnCFierce

> The Federal Trade Commission will try to halt Grifols's $3.3 billion acquisition of Talecris Biotherapeutics Holdings. It's the second time the FTC has stopped a Talecris sale based on antitrust issues. Report

> German biopharmaceutical company Antisense Pharma has released results from its Phase IIb study of trabedersen on malignant brain tumors. The drug had a significant impact on two-year survival and response rates. Antisense release

> Zalicus received a $244,000 grant to continue developing its Phase II product candidate Synavive, a potential rheumatoid arthritis therapy. Zalicus release

> Hyperion Therapeutics' glycerol phenylbutyrate, a urea cycle disorder therapy, has met its primary endpoint in a Phase III study. The 4-week, 46 patient study was conducted in June 2009. Hyperion release

> Patients taking inhaled corticosteroids are at increased risk of developing Type 2 diabetes, and more so with higher doses. Release

And Finally... Illicit drugs' allure is no new news; an exhibit at London's Wellcome Collection looks back at the use, benefits and issues of hallucinogens, cannabis and even espresso coffee throughout history and culture. Article